US FDA Agrees With Only Comment On OTC Drug Naming Draft Guidance: More Time To Comment
Executive Summary
FDA granted CHPA request for more time to comment on December draft guidance, “Developing Proprietary Names for Human Nonprescription Drugs.” CHPA said industry is conducting an ‘in-depth’ review of the principles of the draft.